|
|
Article: NTI Launching Phase III With Anti-Stroke Enzyme.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
With an FDA agreement in hand for the Phase III trial testing its thrombin-like enzyme against acute ischemic stroke, Neurobiological Technologies Inc. said patients will start enrolling in the next few weeks.
NTI's stock (NASDAQ:NTII) closed Monday at $3.05, down 3 cents.
The trial is expected to last "about 18 months," said Paul Freiman, president and CEO of Emeryville, Calif.-based NTI.
The defibrinogenating thrombin-like enzyme, Viprinex (ancrod), is derived from the venom of the Malayan pit viper, and NTI acquired it more than a year ago in the buyout of Empire Pharmaceuticals Inc., of Greenville, N.Y. (See ...